Molecular evolution using the tools of phage, yeast, mammalian, and other display methods have yielded a staggering array of monoclonal and multispecific antibodies, antibody-drug conjugates, immunotherapies, and numerous other constructs. The emergence of computational tools is being applied to improve selection, design, efficacy of candidates, and predictive measures of success, in the translation to effective drug candidates. Conditional activation approaches will allow drug molecules to hit the tumor before they become activated, reducing off-target toxicity and adverse events. Strategies to develop synthetic libraries and in vivo selection will be explored, along with the use of phage display to alter the functional activity of antibodies. Join the faculty at the cornerstone of the PEGS Europe Summit, the 10th Annual Display of Biologics conference, to hear about progress and approaches leading to new classes of therapy.
Scientific Advisory Board:
Joao Goncalves, PhD, Professor, Faculty of Pharmacy, University of Lisbon
René Hoet, PhD, Chief Innovation Officer, FairJourney Biologics
Ahuva Nissim, PhD, Professor, Antibody and Therapeutic Engineering,
William Harvey Research Institute, Queen Mary University of London
E. Sally Ward, PhD, Director, Translational Immunology; Professor,
Molecular Immunology, Centre for Cancer Immunology, University of Southampton